Loading clinical trials...

Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy | Clinical Trials | Clareo Health

COMPLETEDNA

Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy

Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy. Randomised Controlled Study

NCT03391830•Mansoura University

View on ClinicalTrials.gov

Summary

To evaluate the benefit for statin use in prevention of of CI-AKI after computed tomography urogram (CTU).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Planned computed tomography urogram (CTU)
•Statin naive, or not on statin treatment for at least 14 day

Exclusion Criteria

•History of liver disease or elevated serum transaminases
•History of rhabdomyolysis or elevated creatinine kinase
•History of iodinated CM use within 14 days before randomization
•History of N-acetylcysteine, metformin or nonsteroidal anti-inflammatory drugs use within 48 hours of the procedure.
•History of hypersensitivity reaction to contrast media
•Pregnancy or lactation
•Acute renal failure
•End-stage renal disease requiring dialysis
•Cardiogenic shock or pulmonary edema
•Multiple myeloma

Locations (1)

Urology and Nephrology Center

Al Mansurah, Aldakahlia, Egypt

Key Dates

Start Date

January 15, 2018

Primary Completion Date

January 1, 2020

Completion Date

January 1, 2020

Last Updated

January 12, 2021

Enrollment

250

ACTUAL participants

Conditions

Contrast-induced NephropathyStatinAscorbic AcidAKI

Interventions

Atorvastatin-Ascorbic acid

DRUG

Placebo

DRUG

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331

Somatostatin Receptor PositiveNETs+6 more

View study

RECRUITINGPHASE2

The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer

NCT05550415

Triple Negative Breast CancerChemotherapy Effect+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy

Inclusion Criteria

Exclusion Criteria

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer

Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.

Clinical Validation of the RENISCHEM L-FABP POC Assay

STREAM Trial - Statins in Multimorbid Older Adults Without Cardiovascular Disease

Contrast Nephropathy Associated FFA